MedTrace Logo

89Zr-DFO-girentuximab Expanded Access Program (EAP)

NCT06090331 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-07-08

No results posted yet for this study

Summary

The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.

Conditions

Interventions

DIAGNOSTIC_TEST

89Zr-DFO-girentuximab

Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.

Sponsors & Collaborators

  • Telix Pharmaceuticals (Innovations) Pty Limited

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06090331 on ClinicalTrials.gov